rss
J Neurol Neurosurg Psychiatry doi:10.1136/jnnp.2007.140012

Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson Disease

  1. Harriet M M Smeding (h.m.smeding{at}amc.uva.nl)
  1. Academic Medical Center, Netherlands
    1. Johannes D Speelman (j.d.speelman{at}amc.uva.nl)
    1. Academic Medical Center, Netherlands
      1. Hilde M Huizenga (h.m.huizenga{at}uva.nl)
      1. Department of Psychology, University of Amsterdam, Netherlands
        1. P Richard Schuurman (p.r.schuurman{at}amc.uva.nl)
        1. Academic Medical Center, Netherlands
          1. Ben Schmand (b.schmand{at}amc.uva.nl)
          1. Academic Med Center/Univ of Amsterdam, Netherlands
            • Published Online First 21 May 2009

            Abstract

            Objective: To find predictors of cognitive decline and quality of life one year after bilateral subthalamic nucleus stimulation (STN DBS) in Parkinson’s disease (PD).

            Methods: A total of 105 patients were evaluated with a comprehensive neuropsychological assessment before and 12 months after surgery. A control group of 40 PD patients was included to control for effects of repeated testing and disease progression. We determined individual changes in cognition, mood and quality of life using a statistical method that controls for multiple comparisons. We performed logistic regression analyses to assess predictors of cognitive changes and quality of life.

            Results: Twelve months after surgery, the improvement in motor function was 41% (UPDRS3 score in off). The STN group showed a large improvement in quality of life compared to the control group (Cohen’s d=0.9). At the individual level, 32 percent (95% CI: 22 – 40) of the STN group showed a substantial improvement in quality of life. Thirty six percent (95% CI: 27 - 46) of the STN patients showed a profile of cognitive decline compared to the control group. Mood improved in 16 STN patients and declined in 16 subjects. Impaired attention, advanced age and a low levodopa response at baseline predicted cognitive decline, whereas a high levodopa response at baseline predicted improvement in quality of life. Postoperative decrease in dopaminergic medication was not related to cognitive decline.

            Conclusions: STN DBS improves quality of life. However, a profile of cognitive decline can be found in a significant number of patients. Levodopa response, age and attention at baseline are predictors of cognitive and psychosocial outcome.

            Register for free content

            The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

            Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

            BMJ Careers - Latest neurology and neurosurgery jobs